Protocol Details
Studies on Thyroid Nodules and Thyroid Cancer
This study is currently recruiting participants.
Summary
Number |
77-DK-0096 |
Sponsoring Institute |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Recruitment Detail |
Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 6 Mo
Max Age: 98 Years |
Referral Letter Required |
No |
Population Exclusion(s) |
None |
Keywords |
Thyroid Fine Needle Biopsy;
Radioiodine;
Dosimetry;
Natural History |
Recruitment Keyword(s) |
None |
Condition(s) |
Hurthle Cell Thyroid Cancer;
Tall Cell Variant Thyroid Cancer;
Follicular Thyroid Cancer;
Thyroid Cancer;
Papillary Thyroid Cancer |
Investigational Drug(s) |
None |
Investigational Device(s) |
None |
Intervention(s) |
Drug: 68-Gallium Dotatate
|
Supporting Site |
National Institute of Diabetes and Digestive and Kidney Diseases |
Participants in this study will be patients diagnosed with or suspected to have a thyroid nodule or thyroid cancer.
The main purpose of this study is to further understand the methods for the diagnosis and treatment of thyroid nodules and thyroid cancer. Many of the test performed are in the context of standard medical care that is offered to all patients with thyroid nodules or thyroid cancer. Other tests are performed for research purposes. In addition, blood and tissue samples will be taken for research and genetic studies.
Eligibility
INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
1. Male or female, adults or children >= 6 months+.
2. Patients with known or suspected thyroid nodules and/or thyroid cancer.
3. At risk family members of patients who have a genetic susceptibility to developing thyroid cancer.
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
1. Serious underlying medical conditions that restrict diagnostic testing or therapy such as renal failure, congestive cardiac failure or active coexisting non-thyroid carcinoma requiring intervention before thyroid cancer is addressed.
Citations:
Klubo-Gwiezdzinska J, Wartofsky L. The Role of Molecular Diagnostics in the Management of Indeterminate Thyroid Nodules. J Clin Endocrinol Metab. 2018 Sep 1;103(9):3507-3510. doi: 10.1210/jc.2018-01081. PMID: 30032182; PMCID: PMC6456919.
Thakur S, Tobey A, Daley B, Auh S, Walter M, Patel D, Nilubol N, Kebebew E, Patel A, Jensen K, Vasko V, Klubo-Gwiezdzinska J. Limited Utility of Circulating Cell-Free DNA Integrity as a Diagnostic Tool for Differentiating Between Malignant and Benign Thyroid Nodules With Indeterminate Cytology (Bethesda Category III). Front Oncol. 2019 Sep 18;9:905. doi: 10.3389/fonc.2019.00905. PMID: 31620364; PMCID: PMC6759775.
Contacts:
Clinical Trials Number:
NCT00001160